Pathology Department Announces 2021 Faculty Promotions
Chen Liu, MD, PhD, Chair of the Yale Department of Pathology, recently announced the 2021 Faculty Promotions. The 2021 promotion cycle included Natalia Buza, MD, Professor of Pathology, and Themis Kyriakides, PhD, Professor of Pathology, Paul Cohen, MD, Associate Professor of Pathology, Peter Gershkovich, MD, MHA, Associate Professor of Pathology, and Kurt Schalper, MD, PhD, Associate Professor of Pathology.
The Understanding of Immunotherapy Biomarkers is Rapidly Evolving in Oncology
The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike, said Kurt A. Schalper, MD, PhD, in a virtual presentation during the 5th Annual International Congress on Oncology and Pathology.Source: OncLive
Yale Pathology Professor Receives NIH Award for Breakthrough Cancer Research
The award — granted to just 5% of NIH-funded investigators —ensures that Kurt Schalper’s research will be funded for the next seven years. It supports his groundbreaking work identifying novel pathways for cancer immunotherapy which can be used to optimally select and treat patients with non-small cell lung cancer.Source: YaleNews
Yale Cancer Center Scientists Advise Caution in Immunotherapy Research
In a new study, Yale Cancer Center scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.
Yale enhances its cytometry capabilities
The methods and equipment used to probe cellular questions are rapidly advancing—including, at Yale, through the addition in 2014 of CyTOF, or Cytometry Time-Of-Flight, and this past June of the CyTOF Imaging Mass Cytometer (IMC), which greatly expands Yale's ability to examine specimens that are analyzed both for clinical diagnosis and for basic research.Source: Medicine@Yale
New tool helps identify lung cancer patients who will respond to immune therapies
A Yale-led team of researchers has developed a new assay, or investigative tool, to measure the anti-tumor immune activity in non-small cell lung cancer tumors that could lead to a more accurate determination of which patients will respond to immune therapy drugs. Findings from the study were published in the Journal of the National Cancer Institute.